Nektar Therapeutics (NKTR) Total Liabilities (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Total Liabilities of $187.1 million for Q1 2026, down 22.86% year-over-year from $242.5 million in Q1 2025, and down 1.85% quarter-over-quarter from $190.6 million in Q4 2025.
Nektar Therapeutics (NKTR) Total Liabilities (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $187.1 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 22.86% year-over-year to $187.1 million; the TTM figure through Mar 2026 stood at $187.1 million (down 22.86% YoY), while the FY2025 annual figure was $190.6 million, down 21.61% from the prior year.
- Total Liabilities for Q1 2026 stood at $187.1 million, down from $190.6 million in the prior quarter.
- The five-year high for Total Liabilities was $416.2 million in Q1 2022, with the low at $187.1 million in Q1 2026.
- The 5-year median for Total Liabilities is $267.0 million (2023), against an average of $282.6 million.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities fell 26.27% in 2023, then fell 8.41% in 2024.
- Nektar Therapeutics' Total Liabilities stood at $344.0 million in 2022, then fell by 22.36% to $267.0 million in 2023, then dropped by 8.96% to $243.1 million in 2024, then retreated by 21.61% to $190.6 million in 2025, then retreated by 1.85% to $187.1 million in 2026.
- Business Quant data shows NKTR's Total Liabilities at $187.1 million in Q1 2026, $190.6 million in Q4 2025, and $216.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 187.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 187.06 Mn |
| Dec 31, 2025 | 190.57 Mn |
| Sep 30, 2025 | 216.26 Mn |
| Jun 30, 2025 | 231.75 Mn |
| Mar 31, 2025 | 242.50 Mn |
| Dec 31, 2024 | 243.11 Mn |
| Sep 30, 2024 | 259.08 Mn |
| Jun 30, 2024 | 263.65 Mn |
| Mar 31, 2024 | 269.31 Mn |
| Dec 31, 2023 | 267.05 Mn |
| Sep 30, 2023 | 282.88 Mn |
| Jun 30, 2023 | 297.32 Mn |
| Mar 31, 2023 | 320.88 Mn |
| Dec 31, 2022 | 343.96 Mn |
| Sep 30, 2022 | 368.78 Mn |
| Jun 30, 2022 | 403.26 Mn |
| Mar 31, 2022 | 416.23 Mn |
| Dec 31, 2021 | 437.68 Mn |
| Sep 30, 2021 | 475.70 Mn |
| Jun 30, 2021 | 466.38 Mn |